BRD3308

Research use only, not for human use.

BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM.

BRD3308 is a potent, selective HDAC3 inhibitor with IC50 of 54 nM, displays >20-fold selectivity over HDAC1 and HDAC2, >500-fold selectivity over other HDAC isoforms; attenuates PE-mediated phosphorylation of ERK, but not JNK; also activates HIV-1 transcription in the 2D10 cell line, induces outgrowth of HIV-1 from resting CD4+ T cells isolated from antiretroviral-treated, aviremic HIV+ patients ex vivo and disrupts HIV-1 latency; suppresses pancreatic β-cell apoptosis induced by inflammatory cytokines or glucolipotoxic stress, and increases functional insulin release.

RT-PCR Cell Line:2D10 cells Concentration:5 μM, 10 μM, 15 μM, or 30 μM Incubation Time:6 hours, 12 hours, 18 hours, or 24 hours Result:An increase in HIV-1 expression was observed.

——

BRD 3308

Cell Cycle/DNA Damage

HDAC

HDAC

Metabolic Disease

——

1550053-02-5

287.294

C15H14FN3O2

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (870.20 mM)

O=C(NC1=CC=C(F)C=C1N)C2=CC=C(NC(C)=O)C=C2

4-Acetylamino-N-(2-amino-4-fluorophenyl)-benzamide

(-20℃)

With Ice Pack

≥ 2 years